The therascreen PITX2 RGQ PCR assay is an optimized in vitro DNA methylation-specific quantitative real-time PCR test intended for the determination of the percent methylation ratio (PMR) in the pituitary homeobox 2 (PITX2) transcription factor gene promoter 2. The test uses bisulfite-converted genomic DNA derived from formalin-fixed paraffin-embedded tumor tissues of breast cancer patients. The PMR will aid clinicians in selecting adjuvant systemic chemotherapy, e.g. anthracycline-based chemotherapy in high-risk lymph node-positive, estrogen receptor-positive, HER2-negative breast cancer patients. The assay is intended to be used by qualified users, such as technicians, molecular biologists/clinical chemists, or physicians, trained in molecular biology techniques and in vitro diagnostic procedures. The complete workflow is streamlined for medium sample throughput with highly reliable and robust readout and can be performed in two working days.
Introduction Somatic mutations acquired in key signalling pathway, transcription factor, spliceosome, epigenetic and tumor suppressor genes are of central importance in the development and progression of myeloid malignancies including myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). To date, in order to evaluate all relevant genetic alterations, multiple tests are needed, requiring large amounts of DNA. As tests are typically performed sequentially this unnecessarily extends the time between sample acquisition and mutation detection. The QIAact Myeloid DNA UMI Panel in combination with the QIAGEN GeneReader NGS System provides a single solution to simultaneously test for actionable mutations, whilst also saving sample material (only 40ng DNA input required per sample), shortening test time and enabling simplification of lab operations. The QIAact Myeloid DNA UMI Panel is a multi-gene targeted sequencing panel designed to detect complex mutations throughout the most informative genes linked to myeloid disease. This allows reliable and sensitive detection of single nucleotide variants (SNV) and large Insertion/Deletion (InDel) mutations. Methods The QIAact Myeloid DNA UMI Panel targets 25 genes known to be important in myeloid leukemia. A key feature of the panel is the addition of a unique molecular index (UMI) to tag each individual original DNA molecule prior to target enrichment by PCR. UMIs enable sequencing and PCR bias corrections, allowing sensitive detection of mutations. To assess the assay performance, reference standards and blood and bone marrow samples were used. Following target enrichment, libraries were sequenced on the GeneReader NGS System and mutations analyzed using the QIAGEN Clinical Insight (QCI) Analyze software suite. Results To confirm DNA mutation detection, Horizon Discovery and SeraCare Reference Standards containing variants typical of myeloid malignancies were used. The anticipated DNA mutations were consistently identified both within and between runs. The samples used, including blood and bone marrow samples, demonstrated the ability of the assay to detect important large indels (52 bp deletion CALR type 1 variant) and key SNVs down to a minor allele fraction (MAF) of 1% for JAK2 (e.g. exon 12, 13, 14 & 15) and KIT (exon 8, 9, 10, 11 & 17). A sensitive variant detection of allele frequency <0.5% for the KIT D816V was also achieved. For the other genes covered by the panel, including ASXL1, RUNX1, NPM1, DNMT3A, IDH1/2, results show sufficiently uniform amplification and sequencing coverage to support mutation detection with a MAF of 5%. Conclusion The QIAact Myeloid DNA UMI Panel in combination with the QIAGEN GeneReader NGS System offer a fully integrated DNA to variant detection and interpretation solution. The optimized chemistry allows superior analytical sensitivity resulting in accurate and efficient mutation detection of highly relevant genetic alterations for myeloid malignancy research. Disclosures Laloux: QIAGEN France S.A.S: Employment. Biglia:HalioDx: Employment. Bona:HalioDx: Employment. Lafi:HalioDx: Employment. Charifi:HalioDx: Employment. Larsen:QIAGEN Aarhus: Employment. Lueerssen:QIAGEN Manchester Ltd: Employment. Gupta:QIAGEN Aarhus: Employment. Lauber:QIAGEN GmbH: Employment. Hughes:QIAGEN Manchester Ltd: Employment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.